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Although essential for T cell function, the identity of
the T cell receptor ‘‘inside-out’’ pathway for lympho-
cyte function-associated antigen 1 (LFA-1) adhesion
has proved elusive. Here, we define the ‘‘inside-out’’
pathway mediated by N-terminal SKAP1 (SKAP-55)
domain binding to the C-terminal SARAH domain of
RapL. TcR induced Rap1-RapL complex formation
and LFA-1 binding failed to occur inSkap1/primary
T cells. SKAP1 generated a SKAP1-RapL-Rap1
complex that bound to LFA-1, whereas a RapL muta-
tion (L224A) that abrogated SKAP1 binding without
affecting MST1 disrupted component colocalization
in vesicles as well as T cell-dendritic cell (DC) conju-
gation. RapL expression also ‘‘slowed’’ T cell motility
in D011.10 transgenic T cells in lymph nodes (LNs),
an effect reversed by the L224A mutation with
reduced dwell times between T cells and DCs. Over-
all, our findings define a TCR ‘‘inside-out’’ pathway
via N-SKAP1-C-RapL that regulates T cell adhesion,
motility, and arrest times with DCs in LNs.
INTRODUCTION
Integrins regulate multiple aspects of immunity including
migration to sites of inflammation, migration to in lymph nodes
(LNs), and conjugate formation between T cells and antigen-
presenting cells (APCs) (Dustin et al., 2004; Hogg et al., 2003;
Germain et al., 2006). They comprise as many as 20 a-b hetero-
dimers whose binding is affected by altered conformation and
clustering (Hynes, 2002; Carman and Springer, 2003; Dustin
et al., 2004; Hogg et al., 2003). T cell function is regulated by
the b2 family members such as lymphocyte function-associated
antigen [LFA-1; aL(CD11a)-b2 (CD18)] and a4 integrins such as
a4b1 (VLA-4). LFA-1 binds to intercellular adhesion molecules
(ICAM)-1 and -2 on major histocompatibility complex (MHC)-
bearing APCs (Kupfer 2006; Dustin, 2005). Although LFA-1 is
constitutively expressed in a low-affinity form in resting T cells,antigen-receptor complex (TcRz-CD3) and chemokine receptor
ligation generates ‘‘inside-out’’ signals that activate integrins
(Kinashi, 2005). LFA-1 a and b subunits create a headpiece
formed by a b-propeller domain of the a subunit that interacts
with a dinucleotide fold domain in the b subunit termed the
I-like domain (Takagi et al., 2002). Increased affinity involves
exposure of the I domain ligand binding site, whereas clustering
reduces the dissociation rate of binding (Sarantos et al., 2005).
Over the past decade, it has been of major interest to identify
make-up of the ‘‘inside-out’’ signaling pathway. TcRz-CD3
signaling mediators influence adhesion including CD4- and
CD8-p56lck (Rudd et al., 1994), interleukin 2 (IL-2)-inducible
T cell kinase (ITK) (Labno et al., 2003), the guanine nucleotide
exchange factor Vav-1 (Collins et al., 1997; Krawczyk et al.,
2002), phosphatidylinositol 3-kinase (PI 3K) (Shimizu et al., 1995),
GTP binding proteins such as Rac-Rho (Collins et al., 1997;
Mor et al., 2007) and Rap1 (Bivona et al., 2004; Kinashi, 2005)
and its binding partner RapL (regulator of cell adhesion and
polarization enriched in lymphoid tissues) (Katagiri et al., 2003;
2006), and RIAM (Rap1-interacting adaptor molecule) (Lafuente
et al., 2004). In addition, adaptors SLP-76 (76-kD src homology
2 domain-containing leukocyte phosphoprotein) (Kuhne´ et al.,
2003), ADAP (adhesion and degranulation–promoting adaptor
protein) (official gene name designation: Fyb) (Griffiths et al.,
2001; Peterson et al., 2001; Geng et al., 2001), and SKAP1 (src
kinase-associated phosphoprotein 1: official gene name desig-
nation; also SKAP-55, src kinase-associated phosphoprotein-
55) (Wang et al., 2007; Wang et al., 2003; Jo et al., 2005; Kliche
et al., 2006) have been implicated. The challenge has been to
distinguish specific effectors of LFA-1 adhesion from the generic
events needed for cell integrity and function.
One model involves Rap1 and its binding partners RapL and
RIAM (Kinashi, 2005). Rap1 was first implicated in adhesion by
Rap1A overexpression (Bos et al., 2001; Kinashi, 2005) and in
transgenic Rap1V12 T cells (Sebzda et al., 2002). RIAM contains
a Ras association (RA) domain and a PH (pleckstrin homology)
domain and interacts with talin, SKAP1, and Ena (VASP) proteins
(Lafuente et al., 2004; Me´nasche´ et al., 2007; Lee et al., 2009).
RapL (also MAXP1, NORE1B, and RASSF3) is an immune cell
isoform of the RASSF5 (Ras association domain family 5) family
(Katagiri et al., 2003, 2006; Tommasi et al., 2002). It has an
unique N-terminus followed by a RA and C-terminal coiled-coilImmunity 32, 541–556, April 23, 2010 ª2010 Elsevier Inc. 541
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Figure 1. RapL-Rap1 Complex Fails to Form in Skap1/ Primary
T Cells
(A) T cells from wild-type Skap1+/+ and Skap1/ mice were ligated with anti-
CD3 and subjected to precipitation with anti-Rap1 followed by blotting with
anti-RapL (upper panel), anti-SKAP1 (middle panel), or anti-Rap1 (lower
panel).
(B) Cytosolic and membrane fractions of Skap1+/+ and Skap1/ T cells were
blotted with anti-SKAP1 (upper panel), anti-Rap1 (upper-middle panel), anti-
RapL (lower middle panel), or anti-actin (lower panel).
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SKAP1-RapL Mediation of TCR ‘‘Inside-Out’’ Pathway(SARAH) domain (Katagiri et al., 2003). The RA domain binds
GTP-bound active Rap1, whereas the SARAH domain binds
the coiled-coil domain of the serine kinase MST-1 (Katagiri
et al., 2006; Zhou et al., 2008).
A competing model involves immune cell-specific adaptors
SLP-76, ADAP, and SKAP1 in which TCR induces SLP-76
binding to ADAP that in turns binds to SKAP1 (Rudd, 1999;
Jordan et al., 2003; Samelson, 2002; Wang and Rudd, 2008).
ADAP is composed of a unique NH2-terminus, an internal SH3
domain, two nuclear localization sequences (NLSs), and a
C-terminal SH3-like domain (da Silva et al., 1997; Musci et al.,
1997). p59fynT preferentially phosphorylates two YDDV motifs
for SLP-76 SH2 domain binding (Veale et al., 1999; Raab et al.,
1999). Loss of the YDDV sites reduces LFA-1-ICAM1 adhesion,
T cell-APC conjugate formation, and assembly of the peripheral
supramolecular activation complex (pSMAC) (Wang et al., 2004).
ADAP binds to the adaptor SKAP1, which has a unique NH2-
terminal region followed by a PH domain and a COOH-terminal
SH3 domain (Marie-Cardine et al., 1997; Liu et al., 1998;
Marie-Cardine et al., 1998; Kang et al., 2000). Binding is medi-
ated primarily by SKAP1 SH3 domain binding to a proline-rich
region in ADAP, and ADAP-SH3-like domain to a unique
sequence in SKAP1 (Liu et al., 1998; Marie-Cardine et al.,
1998; Kang et al., 2000). ADAP also protects SKAP1 from
proteolytic degradation (Huang et al., 2005). Retroviral transduc-
tion and shRNA knockdown first implicated SKAP1 in adhesion
(Jo et al., 2005; Geng et al., 1999, 2001; Duke-Cohan et al.,
2006), whereas deletion of the SKAP1 SH3 domain or expression
of a peptide encoding the ADAP proline region ablates adhesion
(Wang et al., 2003; Kliche et al., 2006). Both Fyb/ andSkap1/
primary T cells show defective LFA-1 adhesion (Griffiths et al.,
2001; Peterson et al., 2001; Wang et al., 2007). Unlike Fyb/
T cells that show the concurrent loss of SKAP1 expression,
Skap1/ T cells retain ADAP expression and yet still show
defective adhesion (Wang et al., 2007). These observations iden-
tified SKAP1 as an effecter of the ADAP-SKAP1 module,
although the molecular basis for this function has not been
established. The requirement for SKAP1 varies with the strength
of the TCR signal (Wang et al., 2007; Mueller et al., 2007; Wang
and Rudd, 2008).
Although the Rap1-RapL-RIAM and SLP-76-ADAP-SKAP1
modules are needed for LFA-1 adhesion, the identity of the
TcRz-CD3 induced ‘‘inside-out’’ signaling pathway has not
been resolved. In this study, we define a pathway to account
for TcR ‘‘inside-out’’ signaling that integrates the SKAP1 and
Rap1-RapL pathways. ADAP-SKAP1 and Rap1-RapL modules
comprise a single pathway coordinated by SKAP1 in the regula-
tion of LFA-1 adhesion leading to reduced T cell migration in LNs.
RESULTS
Rap-1-RapL Complex Does Not Form in Skap1/
Primary T Cells
Rap1 binding to RapL is a necessary step in the upregulation of
LFA1-mediated adhesion (Kinashi, 2005). At the same time,
SKAP1-deficient T cells elicit defective adhesion (Wang et al.,
2007). To test for a connection between these proteins, we
initially assessed anti-CD3 induced Rap1-RapL complex forma-
tion in freshly isolated primary T cells from spleens of Skap1+/+542 Immunity 32, 541–556, April 23, 2010 ª2010 Elsevier Inc.and Skap1/ mice (Wang et al., 2007). T cells were stimulated
with anti-CD3, lysed, and subjected to precipitation with
anti-Rap1, followed by blotting with anti-RapL or SKAP1
(Figure 1A). Anti-Rap1 coprecipitated RapL from Skap1+/+
T cells (upper panel, lanes 5 and 6), and this increased with
anti-CD3 ligation at 5 min (lane 6 versus 5) and 15 min postacti-
vation (data not shown). This confirmed that anti-CD3 ligation
induces binding of Rap1 to RapL in wild-type T cells (Katagiri
et al., 2003). By contrast, anti-Rap1 failed to coprecipitate
RapL from resting or activated Skap1/ T cells (lanes 7
and 8). Immunoblotting confirmed the presence of RapL and
Rap1 in lysates from Skap1+/+ and Skap1/ T cells (upper and
lower panels, lanes 1–4, respectively). These data showed
that SKAP1 expression is needed for anti-CD3 induction of the
Rap1-RapL complex in primary T cells.
Given this role, we then assessed whether SKAP1 bound to
the Rap1-RapL complex. Indeed, anti-Rap1 coprecipitated
SKAP1 from wild-type cells (middle panel, lanes 5 and 6), and
this increased with anti-CD3 ligation (lane 6 versus 5). Similar
results were obtained when anti-RapL was used for precipitating
antigen (data not shown). Anti-SKAP1 blotting confirmed the
presence of SKAP1 in lysates from Skap1+/+, but not Skap1/
T cells (lanes 1 and 2 and lanes 3 and 4, respectively). These
Immunity
SKAP1-RapL Mediation of TCR ‘‘Inside-Out’’ Pathwaydata indicated that anti-CD3 induces SKAP1 binding to the
Rap1-RapL complex in primary T cells.
SKAP1 Is Needed for RapL Translocation
to the Membrane to Interact with Rap1
To determine the mechanism by which SKAP1 regulates RapL-
Rap1 binding, we isolated cytosolic and membrane fractions
from untreated and anti-CD3 activated T cells and blotted
them with anti-Rap1, anti-RapL, or anti-SKAP1 (Figure 1B).
Although anti-CD3 ligation induced the translocation of a fraction
of RapL from the cytosol to the membrane fraction of wild-type
T cells (lower-middle panel, lane 5 versus 4), it failed to induce
RapL translocation in Skap1/ T cells (lanes 10 versus 9).
SKAP1 also increased membrane binding in response to anti-
CD3 ligation (upper panel, lane 5 versus 4). By contrast, Rap-1
was constitutively associated with the membranes of activated
and nonactivated Skap1+/+ and Skap1/ T cells (upper-middle
panel). The presence of actin served as a loading control (lower
panel). Identical results were observed in Fyb/ (i.e., adap/)
T cells (Figure S1A available online). These results showed that
SKAP1 is needed for anti-CD3-induced RapL translocation to
the membranes of cells where it could interact with Rap1.
SKAP1 Coordinates RapL-Rap1 Binding
To further examine the mechanism of SKAP1 regulation of
Rap1-RapL complex formation, we expressed V5-RapL, myc-
Rap1V12 and GFP-SKAP1 in Jurkat T cells and precipitated
them from cell lysates using anti-myc (Rap1V12) and subse-
quently blotted them with anti-SKAP1, anti-V5 (Rap1), or anti-
myc (Rap1V12) (Figure 2A). Rap1V12 is the constitutively active
form of Rap1. Contrary to a previous report (Katagiri et al., 2003;
Katagiri et al., 2004), coexpression of RapL and Rap1 alone
failed to allow for coprecipitation of V5-RapL with anti-myc
Rap1. No coprecipitated RapL was seen from cytosolic (lanes
3 and 4) and membrane fractions (lanes 7 and 8) or from resting
(lane 3 and 7) or anti-CD3-ligated cells (lanes 4 and 8). Copreci-
pitation was also not observed with different concentrations of
CD3 antibody (1–10 mg/ml; data not shown). By contrast, the
mere coexpression of SKAP1 with RapL and Rap1-V12 resulted
in anti-myc (Rap1V12) coprecipitation of RapL as well as SKAP1
(lane 10). This occurred in the membrane (lane 10), but not in the
cytosolic fraction (lane 6) and required anti-CD3 ligation (lane 10
versus 9). Rabbit anti-mouse served as a negative control
(lane 11). The identity of each band was confirmed by blotting
with individual antibodies, and the expression of endogenous
SKAP1 was low in these cells (data not shown). These data
confirmed that TCR-CD3-induced Rap1-RapL complex forma-
tion required SKAP1.
The same result was obtained when anti-V5 (RapL) was used
to precipitate protein (Figure 2B).Whereas coexpression of Rap1
and RapL failed to allow for anti-V5 (RapL) coprecipitation of
Rap1 (lanes 3 and 4), the coexpression of SKAP1 led to the
coprecipitation of Rap1V12 (lane 6) (lowest band under the light
chain of IgG). Anti-CD3 ligation was needed (lane 6 versus 5).
Anti-myc (Rap1V12) and anti-V5 (RapL) also coprecipitated
SKAP1 as detected by anti-GFP or anti-SKAP1 (Figure 2A,
lane 10 and Figure 2B, lane 17, respectively). This association
also required anti-CD3 ligation (Figure 2A, lane 10 versus 9 and
Figure 2B, lane 17 versus 16, respectively). Conversely, anti-SKAP1 was able to coprecipitate RapL (Figure 2C, lane 5) from
V5-RapL-, myc-Rap1V12-, and GFP-SKAP1-expressing cells
(lane 5 versus 8).
Importantly, active Rap1V12 but not inactive Rap1N17 sup-
ported anti-SKAP1 coprecipitation of RapL (Figure 2D, middle
panel, lane 8 versus 9), and neither SLP-76 nor ADAP (the binding
partner of SKAP1) could substitute for SKAP1 (lanes 10 and 11
versus 8). In this instance, SKAP1, ADAP and SLP-76 were
tagged with HA. This observation indicated that SKAP1 plays
a specific role in promoting Rap1-RapL complex formation that
cannot be replaced by SLP-76 or ADAP. Moreover, this data
indicate that complex formation depends on active Rap1.
Expression of the various proteins was confirmed by blotting of
cell lysates (all panels, lanes 1–5) and in anti-SKAP1 (upper panel,
lanes 7–9), anti-SLP-76 (lane 10), or anti-ADAP precipitations
(lane 11). Taken together, these observations confirmed with
a different approach that SKAP1 was needed for Rap1-RapL
complex formation in T cells and that SKAP1 becomes part of
the complex in response to anti-CD3 ligation.
SKAP1 N-Terminal Domain Binds RapL C-Terminal
Coiled-Coil Domain
Given the requirement for SKAP1 expression for Rap1-RapL
binding, it was important to define the binding site for SKAP1
in the Rap1-RapL complex. Unlike with Rap1V12-RapL coex-
pression, SKAP1 and RapL coexpression alone occasionally
resulted in a low amount of coprecipitation (an example in
Figure 3A, lane 2). Although this binding increased markedly
with RapLV12 expression (lane 4), the observation suggested
that SKAP1 might bind directly to RapL.
To confirm this and define the sites of binding, we used GST
fusion proteins encoding different regions of SKAP1 in a pull-
down assay from lysates of cells transfected with wild-type
V5-tagged RapL or a truncated version of RapL lacking the
C-terminal coiled-coil (SARAH) domain (V5-RapL-Dc2) (Fig-
ure 3B). The pull-down assay with glutathione sepharose beads
was followed by blotting with anti-V5 as previously described
(Raab et al., 1999; Kang et al., 2000). The GST fusion proteins
included full-length SKAP1, N-terminal (N-SKAP1; residues
1–104), SK region (SK; residues 209–285), or N plus PH and
SK regions (N-PH-SK; residues 1–285). Although WT, N, and
N-PH-SK readily precipitated V5-tagged RapL (upper panel,
lanes 3,4, and 6), GST alone and GST-SK failed to precipitate
the protein (lanes 2 and 5, respectively). Anti-GST blotting
confirmed expression of the constructs (lower panel). These
data indicated that the N-terminus of SKAP1 (N-SKAP1) inter-
acts with RapL.
In this assay, deletion of the C-terminal SARAH domain of
RapL (i.e., RapL-DC2) completely abrogated binding to WT, N,
and N-PH-SK RapL (middle panel, lanes 3–6), suggesting that
N-SKAP1 bound to the RapL SARAH domain (i.e., C-RapL). To
test this directly, we incubated GST-SKAP1 domains with
lysates of cells expressing V5-C-RapL and assessed them for
binding (Figure 3C). Full-length SKAP1 WT, N, and N-PH-SK
precipitated C-RapL (lanes 3, 4, and 5), whereas GST alone,
GST-SK, or GST-SH3 failed to precipitate the protein (lanes 2,
6, and 7, respectively). Anti-GST blotting confirmed expression
of the constructs (lower panel). These data indicated that
N-SKAP1 interacts with coiled-coil C-RapL SARAH domain.Immunity 32, 541–556, April 23, 2010 ª2010 Elsevier Inc. 543
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Figure 2. SKAP1 Coordinates RapL-Rap1V12 Complex Formation
(A) Jurkat T cells transfected with RapL-V5, Rap1-myc, and/or SKAP1-GFP were ligated with anti-CD3, separated into cytosolic and membrane fractions, lysed,
and precipitated with anti-myc (myc-Rap1V12). Samples were blotted with anti-V5 (RapL), anti-SKAP1, and anti-myc (Rap1V12).
(B) As in (A) except that anti-V5 (RapL) was used for precipitation and anti-myc (Rap1V12) was used for blotting.
(C) As in (A) except that lysates were precipitated with anti-SKAP1 and then blotted with anti-V5 (RapL).
(D) HA-SKAP1, HA-SLP-76, or HA-ADAP were coexpressed with V5-RapL and/or myc-Rap1V12 or myc-Rap1N17 in Jurkat cells, precipitated with anti-SKAP1,
anti-SLP-76, or anti-ADAP, and blotted with anti-HA (upper panel), anti-V5 (middle panel), or anti-myc (lower panel).
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SKAP1-RapL Mediation of TCR ‘‘Inside-Out’’ PathwayThe structure of related SKAP2 shows an N-terminal four-helix
bundle dimerization domain that packs against an inactive PH
domain (Swanson et al., 2008). Many of the residues including
those needed for dimerization are conserved in SKAP1 (Marie-544 Immunity 32, 541–556, April 23, 2010 ª2010 Elsevier Inc.Cardine et al., 1997; Liu et al., 1998). Dimerization will need to
be released to facilitate PH domain activation. To therefore
assess directly the interaction between N-SKAP1 and C-RapL,
we purified individual N-SKAP1 and C-RapL domains as
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Figure 3. SKAP1 N Terminus, N-SKAP1,
Binds to the C-RapL SARAH Domain
(A) SKAP1-GFP, RapL-V5, and/or Rap1V12-myc
expression in Jurkat cells, followed by precipita-
tion with anti-SKAP1, and blotting with anti-V5
(RapL).
(B) GST-SKAP1 and domains were incubated with
lysates of V5-RapL full-length or V5-RapLDC2-
transfected 293T cells for pull-down assays that
were blotted with anti-V5. The upper and middle
panel show an anti-V5-RapL blot; the lower panel
shows an anti-GST blot.
(C). As in (B) except that cells were transfected
with V5-RapL-SARAH and blotted with anti-V5
(upper panel) or anti-GST (lower panel).
(D) Isothermal titration calorimetry (ITC) of binding
between N-SKAP1 and GST-C-RapL. Status of
purified proteins detected by silver staining are
shown in Figure S1.
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SKAP1-RapL Mediation of TCR ‘‘Inside-Out’’ PathwayGST-fusion proteins, and purification was followed by Factor X
cleavage (see Experimental Procedures). Silver staining of
material showed the presence of individual subunits without
contaminating material (Figure S1B). An interaction between
these proteins was then examined with isothermal titration
calorimetry (ITC), a method that measures stoichiometry,
binding constants, and thermodynamic parameters in a single
interaction (Figure 3D). The ITC data determined at 25C clearly
demonstrated that the SARAH RapL C-terminal coiled-coil
domain interacts directly with N-SKAP1 with a stoichiometry
that approximates to unity (n = 0.85). The equilibrium dissocia-
tion constant, Kd, of 0.6 uM corresponds to a change in free
energy of binding (DG) of 8.5 kcal/mol. The change in enthalpy
of binding is relatively small (DH = 2.3 kcal/mol) and hence,
at the experimental temperature, the interaction is entropy driven
(T DS = 6.2 kcal/mol). This is likely to indicate that the interaction
is accompanied by a substantial contribution from the release of
solvent molecules from the surface area that is buried on forming
the complex. These observations indicated that the N-SKAP1
binds directly and on a one-to-one basis to the C-RapL SARAH
domain.
RapL-L224A Mutation Selectively Disrupts SKAP1
without Affecting MST-1 Binding
N-SKAP1 binding to C-RapLwas next confirmed by deletion and
mutation analysis (Figure 4A). RapL mutants tested included
RapLDC (residues 1–222; lacking the entire SARAH-coiled-coil
domain), RapLDC2 (residues 1–243; lacking part of the SARAH
domain), RapLDC3 (residues 1–254; C-terminal and outsideImmunity 32, 541–5the SARAH domain) or, alternatively, full-
length RapL with point mutations at resi-
dues L224A (RapL-L224A) and L253A
(RapL L253A) within the coiled-coil
domain. Whereas anti-SKAP1 precipi-
tated wild-type and the RapLDC3 mutant
(lanes 7 and 10, respectively), it failed to
precipitate the RapLDC2 and RapLDC
mutants (lanes 8 and 9, respectively).
Each of the V5-tagged constructs andGFP-SKAP1 was expressed as seen in cell lysates (upper and
lower panels, lanes 1–6).
The same result was obtained in GST pull-down assays (Fig-
ure 4B). WT V5-RapL, V5-RapL-L224A, and V5-RapL-L253A
were expressed and assessed for binding to the different regions
of SKAP1. Although the N-SKAP1 precipitated WT RapL and
the L253A mutant (upper and lower panels, lane 4), it failed to
precipitate the L224A single-site mutant (middle panel, lane 4).
These data showed by two independent approaches that the
RapL-L224A mutation disrupts SKAP1 N-terminal binding.
Whereas N-SKAP1 bound to the SARAH domain, the serine-
threonine kinase MST-1 has also been reported to bind to
the same region in RapL (Katagiri et al., 2006). For defining the
function of the SKAP1-RapL interaction, and distinguishing it
from the MST-1-RapL interaction, it was therefore necessary to
identify a RapL mutant that abrogated SKAP1 binding without
affecting the binding of MST1. To assess MST-1 binding to
RapL, we coexpressed myc-MST-1 and V5-tagged RapL, pre-
cipitated an anti-myc MST-1, and blotted with anti-V5 for RapL
(Figure 4C). Coexpression of MST-1 and RapL showed clear
binding (lane 1), consistent with previous reports (Katagiri et al.,
2006). However, unlike SKAP1, MST-1 also bound to the L224A
mutant (lane 5 versus 1, 4, and 6) (see normalized densiometric
values). By contrast, as a control, deletion of the coiled-coil
domain inRapLDCandRapLDC2eliminatedMST-1binding, con-
firming binding to the SARAH domain (lanes 2 and 3 versus 1).
Rabbit anti-mouse served as a negative control (lane 7).
Confirmation of the overlap in binding to the C-RapL SARAH
domain was also seen in SKAP1 andMST1 coexpression studies56, April 23, 2010 ª2010 Elsevier Inc. 545
1 2 3 4 5 6
W
T
Δ C ΔC
2
ΔC
3
L2
24
A
L2
53
A
W
T
ΔC ΔC
2
ΔC
3
L2
53
A
L2
24
A
Lysate
+ GFP SKAP1
Co
n
tro
lI
P
V5-RapL
GFP-SKAP1
Blot:
Anti-V5
Anti-GFP
A
+ GFP SKAP1
7 8 9 10 11 12 13
W
T
ΔC ΔC
2
ΔC
3
L2
53
A
L2
24
A
Anti-Myc (MST-1) IP
+ Myc MST-1
V5 RapL
Myc-MST-1
Co
n
tro
lI
P
1 2 3 4 5 6 7
Blot:
Anti-V5
Anti-Myc
W
T
ΔC ΔC
2
ΔC
3
L2
53
A
L2
24
A
Ly
sa
te
V5-RapL-WT
GS
T
WT N SK N-P
H-
SK
V5-RapL-L224A
V5-RapL-L253A
1 2 3 4 5 6
Blot:
Anti-V5
B
1,0
0,8
0,6
0,4
0,2
0R
ap
L/
M
ST
1 
ra
tio
V5-RapL
Blot:
Anti-Myc
Anti-V5
Anti-GFP
Myc-MST1
GFP-SKAP1
Lysate
V5-RapL
Myc-MST1
Anti-Myc IP
V5-RapL
Myc-MST1
Anti-V5 IP
GFP-SKAP1
V5-RapL
Myc-MST1
Flag-RIAM
- - 0.1 0.3 3.0 ug SKAP1
- + + + + RapL
+ + + + + MST1
Anti-Myc
Anti-V5
Anti-Flag
Anti-Myc IP
Anti-V5 IP V5-RapL
Myc-MST1
Myc-MST1
V5-RapL
1 2 3 4 5
1 2 3 4 5
1 2 3 4 5
1 2 3 4 5
D
V5-RapL
6 7 8 9 10 1112
GFP-SKAP1Anti-GFP
+ + + + + + +
37
50
kDa
Lys
ate
An
ti-S
KA
P1
IP
An
ti-V
5 (R
apL
) IP
hc
+ + + + + Anti-CD3
Lys
ate
An
ti-M
yc(R
ap1
V1
2) I
P
V5-RapL
Myc-Rap1V12
lc
Blot:
Anti-V5
Blot:
Anti-V5 and
anti-Myc
E
1 2 3 4 5
+ + + + + SKAP1
+ - + - + RapL
- + - + - RapL L224A
+ + + + + Rap1V12
Co
ntr
ol I
P
+ + + + + + +
+ + + + + + +
+ - + - + - +
- + - + - + -
Co
ntr
ol I
P
kDa
37
37
37
kDa
37
75
kDa
37
50
75
kDa
37
50
75
kDa
37
50
25 75
Anti-SKAP1 IP
- - 0.1 0.3 3.0 ug SKAP1
- + + + + RapL
+ + + + + MST1
- - 0.1 0.3 3.0 ug RIAM
- + + + + RapL
+ + + + + MST1
- - 0.1 0.3 3.0 ug RIAM
- + + + + RapL
+ + + + + MST1
RapL L224A
RapL
Rap1V12
SKAP1
Anti-CD3
C
Figure 4. The RapL-L224A Mutant Selectively Ablates SKAP1 Binding
(A) V5-tagged RapL and mutant coexpression with GFP-SKAP1 in 293T cells, followed by precipitation with anti-SKAP1, and blotting with anti-V5 (upper panel)
and anti-GFP (lower panel).
(B) GST-SKAP1 and domains were used to pull-down V5-RapL (upper panel), V5-RapL-L224A (middle panel), or V5-RapL-L253A (lower panel) and then theywere
blotted by anti-V5 (RapL).
(C) V5-tagged RapL and domains were coexpressed with Myc tagged-MST-1; this coexpression was followed by precipitation with anti-myc and blotting with
anti-V5 (upper panel) or anti-myc (lower panel). The lower histogram shows the ratio of RapL/MST1.
(D) The upper-left panels show the expression of MST-1, RapL, and SKAP1 in cell lysates of transfected cells. The upper-right panels show precipitations from
lysates and blotting as indicated. The lower-left panels show the expression of MST-1, RapL, and RIAM in cell lysates of transfected cells. The lower-right panels
show precipitations from lysates and blotting as indicated.
(E) V5-RapL, V5-RapL-L224A, myc-Rap1, and SKAP1-GFPwere coexpressed in Jurkat T cells; coexpression was followed by anti-CD3 ligation and precipitation
with anti-myc (Rap1V12), anti-SKAP1, or anti-V5 as indicated. Samples were blotted with a combination of anti-V5-myc, anti-V5, and anti-GFP as indicated.
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SKAP1-RapL Mediation of TCR ‘‘Inside-Out’’ Pathway(Figure 4D). V5-RapL and myc-MST1 were initially coexpressed
in Jurkat cells with increasing levels of GFP-SKAP1 as titrated
with 0.1, 0.3, and 3.0 ug/ml of plasmid DNA with additional
GFP control plasmid for maintaining equal levels of DNA. As
shown by blotting of cell lysates, GFP-SKAP1 expression
increased with increasing amounts of the GFP-SKAP1 plasmid
without affecting myc-MST1 or V5-RapL expression (upper left
panel; lanes 2–5). From this lysate, anti-myc precipitates were
then blotted with anti-V5 RapL and anti-myc-MST1 (upper-right
panel). Although anti-myc readily precipitated MST1 and associ-
ated RapL (upper panels, lane 2), increasing SKAP1 expression
reduced the amount of RapL coprecipitated MST1 (lanes 3–5).
Conversely, although anti-V5 RapL coprecipitated MST1 (lower
panels, lane 2), increasing SKAP1 expression reduced levels of
coprecipitated MST1 (lanes 3–5). At the same time, SKAP1
showed an increased binding to RapL (lowest panel; lanes
3–5). As a control, FLAG-tagged RIAM (another protein involved
in adhesion) failed to compete for MST1 binding to RapL with
increasing levels of expression (lower-left and -right panels).
These findings showed that SKAP1 can compete with MST1
for binding to RapL, a result consistent with binding to the
same SARAH domain of RapL.
Given the identification of a L224A mutation that selectively
affected SKAP1 binding, we next assessed whether the
L224A mutation could prevent SKAP1 regulation of the Rap1-
RapL complex. RapL or RapL-L224A was coexpressed with
Rap1V12 in the presence or absence of SKAP1 and examined
for Rap1 precipitation of RapL (Figure 4E). Whereas anti-myc
Rap1 precipitated V5-RapL from SKAP1-, RapL-, and Rap1V12-
transfected cells (lane 3), RapL-L224A failed to support this
(lane 4). Blotting with the respective antibodies confirmed the
presence of Rap1V12 and RapL in cell lysates (lanes 1 and 2).
Anti-SKAP1 also coprecipitated RapL from cotransfected cells
(lane 8), but not from cells with RapL-L224A (lane 9). Anti-RapL
blotting confirmed the presence of RapL expression (lanes 6
and 7). Conversely, anti-V5 RapL precipitated GFP-SKAP1
from cotransfected cells (lower panel, lane 10), but not from
cells expressing RapL-L224A with SKAP1 and Rap1 (lane 11).
These data indicated that N-SKAP1 binding to the RapL-L224
site is the key event needed to regulate Rap1-RapL complex
formation in T cells.
SKAP1-RapL Regulates RapL-Rap1 and SKAP1-RapL
Colocalization
Identification of the RapL-L224 mutant allowed an examination
of the role of N-SKAP1-C-RapL binding in intracellular localiza-
tion (Figure 5). Cells transfected with RapL-CFP, SKAP1-GFP,
and Rap1V12-mcherry were seeded on coverslips with immobi-
lized anti-CD3 and ICAM-1 and imaged at the contact area by
confocal microscopy (Bunnell et al., 2002; Schneider et al.,
2008). Cells with only low-moderate intensities of expression
were imaged so that problemswith protein overexpression could
be avoided. RapL-CFP, SKAP1-GFP, and Rap1V12-mcherry
localized in clusters in resting and anti-CD3-ligated T cells over
0–240 s (Figure 5A, upper panels; Movie S1). Anti-CD3 did not
alter the number or size of the clusters. Further, surprisingly,
RapL-L224A, SKAP1-GFP, and Rap1V12-mcherry also were
found in clusters in cells cotransfected with the RapL-L224A
mutant (lower panels) (Movie S1). No obvious difference wasnoted in the average size or number of clusters in RapL or
RapL-L224A transfected cells (data not shown). All clusters
migrated with a similar pattern and speed (data not shown) along
the peripheral contact region (Figure S2A).
The one difference between RapL and RapL-L224A was in
their colocalization with Rap1 and SKAP1 as determined by
Pearson’s correlation coefficient (PCC) with Volocity software
(right panels). RapL and Rap1V12 showed low PCC values in
resting and anti-CD3 ligated cells (i.e., average PPC = 0.09 and
0.12, respectively) in the absence of SKAP1 (upper panel).
SKAP1 coexpression had little effect on Rap1-RapL colocaliza-
tion in resting cells (i.e., PCC = 0.14); however, it substantially
increased RapL-Rap1V12 colocalization in anti-CD3-activated
cells (i.e., average PCC value = 0.34). Similar values have been
reported for other colocalized proteins (Huse et al., 2006). This
indicated that SKAP1 is needed for RapL-Rap1V12 colocaliza-
tion, an observation consistent with the coprecipitation results
(Figures 1 and 2). In contrast, RapL-L224A failed to support
RapL-Rap1V12 colocalization in resting and anti-CD3-ligated
cells (i.e., average PCC = 0.1 and 0.13, respectively). This was
also observed over the time course of imaging (Figure S2B,
upper panel). Similar differences were also noted in the
SKAP1-RapL colocalization (lower panel) in which the limited
colocalization in resting cells increased with anti-CD3 ligation
(i.e., average PCC = 0.23 and 0.55, respectively). However,
only weak SKAP1 colocalization with RapL-L224Awas observed
in response to anti-CD3 (i.e., average PCC = 0.2), or over a time-
course (Figure S2B).
Similar results were obtained when anti-CD3-CD18 were
copresented on beads (Figure 5B). CD18 (or ITGB2) is the beta
2 subunit that pairs with CD11a of LFA-1. RapL, Rap1V12, and
SKAP1 colocalized at the site of contact with the beads (upper
panel, panels a-d). Much of the fluorescence signal was associ-
ated with vesicular-like structures at the contact region as seen
by translucent microscopy (Figure 5Be; see arrows). By contrast,
coexpressed RapLL224A, Rap1V12, and SKAP1, although
still associated with vesicular structures, failed to colocalize
(lower panel). Less colocalization of vesicles was also observed.
Reduced cluster colocalization was confirmed by PCC values for
Rap1-RapL-RapL224A, SKAP1-RapL-RapL224A, and SKAP1-
Rap1V12 (lower panels). The nature of the vesicles was unclear.
Staining of the vesicles with EEA1 and Rab7, markers of early
endosomes, showed limited overlap with RapL-CFP clusters
(Figure S3).
Incubation for longer periods of time (i.e., 5–15 min) resulted in
the formation of a peripheral region that resembled a peripheral
supra-molecular complex (pSMAC), as described by others
(Kupfer, 2006) (Figure 5C, upper panels). The pSMAC is enriched
with LFA-1, whereas the cSMAC is composed of the TcR, CD28,
and other signaling proteins (Dustin et al., 2004; Kupfer, 2006). In
this case, imaging was conducted at the contact area between
the T cell and anti-CD3 covered coverslip surface. RapL and
SKAP1 both formed a pericentric ring (Figures 5Ca and 5Cb,
respectively) that closely overlapped (Figures 5Cd). Rap1V12
formed a similar pericentric overlapping region together with
additional material in the inner region (Figures 5Cc). By contrast,
coexpression of RapL-L224A with SKAP1 and Rap1V12 showed
a loss of the SMAC-like region, instead showing a diffuse pattern
for RapL-L224, SKAP1, and Rap1V12 at the interface (FiguresImmunity 32, 541–556, April 23, 2010 ª2010 Elsevier Inc. 547
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SKAP1-RapL Mediation of TCR ‘‘Inside-Out’’ Pathway5Ca–5Cd, lower panels). N-SKAP1 binding to C-RapL therefore
regulates the ability of the three components to colocalize in
clusters and in a pSMAC-like formation.
Similar alterations in the formation of the IS as observed
between T8.1 T cells and L625 APCs (Figure 5D). T8.1 cells
express a TcR that reacts with Ttox peptide as presented by
I-Ak on L625 cells (Blank et al., 1993). SKAP1 and RapL in the
T cell colocalized in the circular pattern at the site of contact
with the APC similar to a pSMAC (Figures 5Da and 5Db). Rap1
was found to partially colocalize with circular SKAP1 and
RapL, but was also found in other regions of IS (Figures 5Dc).
RapL-L224A expression disrupted the pSMAC-like structure
for RapL L224A, SKAP1, and Rap1, leaving a more diffuse
pattern at the IS (Figures 5Dd and 5De). These data showed
that N-SKAP1-C-RapL determines the colocalization of RapL,
SKAP1 and Rap1 in both newly formed clusters and in the
more mature synapse of anti-CD3 activated T cells.
N-SKAP1-C-RapL Binding Regulates RapL Binding
to LFA-1
Given this, it was possible that N-SKAP1-C-RapL might control
RapL binding to LFA-1. Jurkat cells were cotransfected
with RapL-RapL-L224A-CFP, SKAP1-GFP, and LFA-1 (CD11a)-
mcherry and imaged by immunofluoresent microscopy (Fig-
ure 6A). Transfected CD11a-mcherry increased ICAM-1 binding
(data not shown). RapL colocalized with CD11a in response to
anti-CD3 ligation as judged by PCC values (i.e., average from
0.14 to 0.45) (example in upper-left panel; lower histogram),
whereas RapL-L224A showed reduced levels of colocalization
(i.e.,  0.18) (upper-right panel; lower histogram).
Binding between RapL and LFA-1 was then assessed bio-
chemically by anti-V5-RapL precipitation from cells expressing
SKAP1, RapL, or RapL-L224A and Rap1V12 followed by blot-
ting with anti-CD18 (Figure 6B). CD18 is the beta 2 subunit
that pairs with CD11a of LFA-1. Anti-V5-RapL failed to precipi-
tate CD18 from cells transfected with RapL and Rap1V12 (lanes
5–8), in neither the cytosolic (lanes 5 and 6) nor membrane
fractions (lanes 7 and 8). By contrast, SKAP1 coexpression
with RapL and Rap1V12 allowed anti-RapL coprecipitation of
CD18 from the membranes of cells in response to anti-CD3
(lane 4). Unlike with wild-type RapL (lower panel, lane 3), coex-
pression of RapL-L224A with SKAP1 and Rap1V12 failed to
coprecipitate LFA-1 from the membrane fraction (lane 4). Simi-
larly, anti-SKAP1 coprecipitated CD18 from membranes of
anti-CD3 activated cells expressing RapL, Rap1, and SKAP1
(Figure 6C, lane 6).Figure 5. RapL224A Disrupts Colocalization and pSMAC Formation
(A) As shown in the left panels, RapL-CFP or RapL-L224A plus SKAP1-GFP and
CD3 coated coverslips and imaged in real-time with a Zeiss confocal microscope
of average PCC values for RapL-Rap1V12 and SKAP1-RapL colocalization.
(B) RapL-CFP, RapL-L224A-CFP, SKAP1-GFP, and/or Rap1V12-mcherry localiza
PPC values for colocalization. (Be) and (Bj) show DIC images (arrows pointing to
(C) RapL/RapL-L224A-CFP, SKAP1-GFP, and Rap1V12-mcherry were coexpress
subpanels (RapL, SKAP1; Rap1-coexpressing cells) show the following: RapL (
SKAP1; Rap1 coexpressing cells) show the following: RapL-L224A (a); SKAP1 (b
(D) Localization of RapL-RapL-L224A-CFP, SKAP1-GFP, and Rap1V12-mcherry
the following: RapL, SKAP1; Rap1 coexpressing cells (a–c): RapL (a); SKAP1 (b), R
(e), Rap1 (f).Lastly, the complex could also be precipitated from primary
Skap1+/+, but not from Skap1/ T cells (Figure 6D). Anti-
SKAP1 coprecipitated endogenous CD18 in a manner depen-
dent on anti-CD3 ligation in Skap1+/+ T cells (lane 4 versus 3).
Conversely, anti-CD18 coprecipitated SKAP1 (middle panel,
lane 6 versus 5). Both anti-SKAP1 and anti-CD18 coprecipitated
RapL with anti-CD3 ligation (lanes 4 versus 3 and 6 versus 5,
respectively). Rabbit anti-mouse served as a negative control
(lane 7).
Further, in a comparison of primary Skap1+/+ versus Skap1/
primary T cells, anti-CD18 coprecipitated SKAP1 (upper panel,
lanes 10 versus 9), RapL (middle panel, lanes 10 versus 9), and
Rap1 (lower panel, lanes 10 versus 9). By contrast, anti-CD18
coprecipitated little if any protein from Skap1/ cells (all panels,
lanes 11 and 12). Collectively, these observations indicated that
SKAP1 expression is needed for the binding of the SKAP1-RapL-
Rap1 complex to LFA-1.
RapL224A Disrupts LFA-1-ICAM1 Binding
and T Cell-Conjugate Formation
It was next important to examine whether SKAP1-RapL binding
was needed for LFA-1-mediated adhesion. T cells were cultured
on tissue culture plates coated with ICAM-1 in the presence or
absence of soluble anti-CD3 and assessed for binding, as
described (Wang et al., 2003) (Figure 7A). In these experiments,
RapL and SKAP1were used to transfect cells, although the addi-
tional coexpression of Rap1V12 gave similar results (data not
shown). Anti-CD3 increased binding of vector-transfected cells
to ICAM-1 cells by 3 to 4-fold. Expression of SKAP1 and RapL
individually increased ICAM1 binding further, whereas SKAP1-
RapL coexpression had a cooperative effect. Neither RapLDC2
lacking RapL coiled-coil (SARAH) domain, nor the RapL-L224A
mutant supported this increase in binding when coexpressed
with RapL (see Figure S4A).
Similarly, RapL-L224A failed to support increased conjugate
formation with APCs (Figure 7B). The T cell/APC ratio corre-
sponds to the number of adherent T cells in a given field (i.e.,
at least three fields with greater than 60 APCs) divided by the
number of APCs in the same field. Although the addition of
Ttox peptide increased conjugate formation by 2-fold (i.e.,
from 0.18 to 0.4 T cell/APC ratio) in the GFP-transfected
control, SKAP1-RapL coexpression increased conjugate forma-
tion by 10-fold (i.e., from 0.18 to 1.2 T cell/APC ratio) (also see
Figure S4B). By contrast, the RapL-L224A mutant failed to
support an increase in conjugation. Overall, these findings
showed that L224A mutant disrupted the cooperative effect ofRap1V12-mcherry were expressed in Jurkat cells and then incubated on anti-
. Insets showed examples of merged colors. The right panels show histograms
tion with beads coupled to anti-CD3/ICAM1 for 10min. The lower panel shows
vesicles).
ed in Jurkat cells responding to plate-bound anti-CD3 for 20–30min. The upper
a); SKAP1 (b); Rap1 (c); and merged (d). The lower subpanels (RapL-L224A,
); Rap1 (c); and merged (d).
in T8.1 cells incubated with L625 cells and Ttox peptide. The subpanels show
ap1 (c); RapL-L224A, SKAP1; Rap1 coexpressing cells (d–f): RapL (d); SKAP1
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Figure 6. SKAP1-Rap1-RapL Is Required for Binding to LFA-1
(A) The upper panels show examples of images of cells at 240 s expressing SKAP1-GFP, RapL-CFP, and LFA-1a-red. The lower panel shows a histogram of
average PCC values.
(B) SKAP1, RapL-Rap1V12, or RapL-Rap1V12 were expressed in Jurkat cells, precipiated with anti-V5 (RapL), and blotted with anti-CD18.
(C) SKAP1 and RapL or SKAP1, RapL, and Rap1V12 were expressed; this was followed by precipitation with anti-SKAP1 and blotting with anti-CD18.
(D) As shown in the upper panel, Jurkat cells untreated or ligated wtih anti-CD3 for 10 min were precipitated with anti-SKAP1 or anti-CD18 and then blotted as
indicated. The lower panel shows T cell splenocytes from wild-type Skap1+/+ (WT) and Skap1/ cells. Skap1+/+ or Skap1/ T cells, unstimulated or ligated with
anti-CD3 for 10 min, were precipitated with anti-CD18 and then blotted with anti-SKAP1 (upper panel), anti-RapL blotting (middle panel), and anti-Rap1 blotting
(lower panel).
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SKAP1-RapL Mediation of TCR ‘‘Inside-Out’’ PathwaySKAP1 and RapL in increasing ICAM1 binding and conjugate
formation.
RapL ‘‘Slows’’ T Cell Motility and Enhances T Cell-DC
Conjugation in LNs
Next T cell motility was imaged in ex vivo isolated LN slices as
previously described (Baje´noff et al., 2006; Asperti-Boursin
et al., 2007). This technique allows the visualization of T cell
movement and interaction with APCs in LNs, as has been550 Immunity 32, 541–556, April 23, 2010 ª2010 Elsevier Inc.observed bymultiphoton microscopy (Bousso and Robey, 2003;
Mempel et al., 2004; Miller et al., 2002; Hugues et al., 2004;
Zinselmeyer et al., 2005; Schneider et al., 2006). Freshly purified
DO11.10 T cells were labeled with CFSE and overlaid on con-
genic LN slices in the presence or absence of OVA peptide
(Figure 7C; Movie S2). Movement was partially dependent on
ICAM1 binding as shown by a 35%–40% reduction in number
of bound cells and in the motility of those that adhered in the
presence of anti-ICAM1 (Figure S5). Vector-transfected T cells
Immunity
SKAP1-RapL Mediation of TCR ‘‘Inside-Out’’ Pathwaywere observed to move randomly over the surface where they
would often enter and reappear along the nodal surface. In the
presence of perfused OVA peptide, T cells reduced their speed
from a mean average speed of 9 to 7 um/ml (Figure 7C, upper
dot plots; p value = 0.005; also Figure S6) and displacement
from the point of origin (i.e., from 28 to 15 mM) (Figure 7C, lower
dot plots). Intriguingly, RapL transfection reduced T cell motility
in the absence and presence of peptide from an average speed
of 6 and 4 um/ml, respectively (Figure 7C, upper dot plots;
Figure S6). The effect of RapL on antigen-reduced displacement
was even more substantial (i.e., 28 to 8 mM) (lower dot plots). By
contrast, the RapL-L224A mutant failed to reduce the velocity in
the absence (p value = 0.1789) or in the presence of OVA peptide
(p value = 0.1543). RapL and L224A mutant were expressed
to a similar degree as detected by FACS analysis in 60%–70%
of the T cells examined (data not shown). These observations
show that RapL slowed T cell movement in a manner dependent
on the L224A SKAP1 binding site.
Dwell times were also measured between T cells and mature
DCs labeled with SNARF7 (Figure 7D; Movie S2). As expected,
the addition of OVA peptide increased the contact times
between T cells and APCs (i.e., from 550 to 700 s) (upper dot
plots). Consistent with an effect on motility, RapL expression
increased the contact times with APCs in the absence of peptide
(i.e., from 550 to 700 s; p value = 0.0006), and prolonged even
further the increased contact time observed in the presence of
peptide (i.e., from 700 to 850 s; p value = 0.0001). By contrast,
the L224A mutant did not increase the dwell times with APCs
in the absence or presence of peptide (p values = 0.3273 and
0.3905, respectively). When scored on the basis of contact
time per incidence (lower panel), control cells showed a majority
of short-term contacts (30%: 300–600 s; 45%: 600–900 s),
whereas RapL increased the percentage of cells to form
longer-term interactions with DCs (39%: 600–900 s; 30%: 900–
1200 s). The loss of SKAP1 binding skewed the majority of inter-
actions back to shorter time periods (32%: 300–600 s; 38%:
600–900 s). These observations show that RapL can increase
dwell times with APCs in LNs in a manner dependent on the
L224A SKAP1 binding site.
DISCUSSION
Whereas TCR ligation generates ‘‘inside-out’’ signals for LFA-1
adhesion, the nature of the pathway has yet to be clarified.
The challenge has been to distinguish specific effectors of
LFA-1 adhesion from generic events. The pathway is central to
immunity given that it regulates T cell migration in LNs and
T cell-APC dwell times. In this study, we have identified an
‘‘inside-out’’ pathway that couples the TCR with the SKAP1
and Rap1-RapL pathways for adhesion. SKAP1 expression
was found to be essential for TCR-driven Rap1-RapL complex
formation in primary T cells, and the binding of the newly formed
SKAP1-RapL-Rap1 complex to the cytoplasmic tail of LFA-1.
N-SKAP1 domain binding to the C-RapL domain connected
the pathways such that a RapL-L224A mutant that selectively
disrupted SKAP1 binding impaired ICAM-1 binding and T cell-
APC conjugate formation. RapL expression also reduced T cell
motility (i.e., ‘‘slowing’’) and increased the T cell-APC dwell times
of D011.10 transgenic T cells with DCs in LN slices, an effectreversed in the L224A mutant. Overall, our findings unite the
ADAP-SKAP1 and Rap1-RapL modules into a single TCR-driven
‘‘inside-out’’ pathway that activates LFA-1 adhesion, slows T cell
motility, and enhances T cell-DC conjugation in LNs.
Previous studies identified two modules for ‘‘inside-out’’
signaling, Rap1-RapL-RIAM and another mediated by adaptors
SLP-76, ADAP, and SKAP1 (Rudd, 1999; Kinashi, 2005; Wang
and Rudd, 2008). We previously showed that Skap/ T cells
expressing ADAP still have reduced LFA-1 adhesion, thus
identifying SKAP1 as an effecter of the SKAP1-ADAP module
(Wang et al., 2007). Our present findings provide an underlying
mechanism of this effecter function by showing that SKAP1
regulates RapL-Rap1 complex formation and its binding to
LFA-1 for clustering. RapL failed completely to translocate to
the membranes of Skap1/ and Fyb/ primary T cells. Further,
RapL and Rap1 failed to form a complex in Skap1/ T cells or in
coexpression studies lacking SKAP1 expression. By contrast,
most Rap1 was constitutively associated with the membranes
of untreated and anti-CD3-treated cells in which anti-CD3 liga-
tion can converts Rap1 into GTP-bound Rap1 (Bos et al.,
2001; Bivona et al., 2004; Schneider et al., 2005). Specificity
was shown by the requirement for anti-CD3 ligation and the
fact that neither ADAP nor SLP-76 could substitute for SKAP1.
Our findings therefore show that ADAP-SKAP1 and Rap1-
RapL are not separate modules, but rather comprise a single
‘‘inside-out’’ pathway that couples the TCR complex with the
upregulation of LFA-1 adhesion. By contrast, chemokine (i.e.,
SDF1 and CCL21) induced LFA-1 adhesion-migration can occur
normally in Skap-1/ cells (Wang et al., 2010).
The TCR ‘‘inside-out’’ pathway was mediated by SKAP1
N-terminal region (N-SKAP1) binding to the coiled-coil SARAH
domain of RapL (C-RapL) as shown by mutational, GST pull-
down studies and isothermal titration calorimetry. ITC measure-
ments of the isolated domains showed a stoichiometry of 0.85
and equilibrium dissociation constant of 0.6 uM, a value in the
range of other interactions in signal transduction (Pawson and
Nash, 2000). RapL can accommodate Rap1-GTP binding to
the RBD domain and SKAP1 binding to C-RapL. By contrast,
SKAP1 competed for MST1 binding to C-RapL, indicating the
existence of at least two types of Rap1-RapL complexes, one
associated with SKAP1 and another with MST1. At the same
time, optimal SKAP1 binding to RapL required active Rap1. In
one scenario, GTP-Rap1 would change the conformation of
RapL for more efficient SKAP1 binding. As a precedent, Rap1
binding to Nore1A is weakened by intramolecular C1 domain
binding (Harjes et al., 2006). Although Rap1 constitutively bound
to membranes, we cannot exclude that a small subset of cyto-
solic Rap1 interacts with SKAP1-RapL to help shuttle the
SKAP1-RapL complex. SKAP1 may also facilitate Rap1 activa-
tion (Kliche et al., 2006). In either case, Rap1-RapL expression
without SKAP1 failed to colocalize with or bind to LFA-1, and
anti-CD18 failed to coprecipitate RapL-Rap1 from Skap1/
primary T cells. Further, the RapL L224A mutation prevented
LFA-1 binding and reduced ICAM-1 adhesion. Within the
complex, RapL is likely to mediate a direct interaction with the
aL tail of LFA-1(Katagiri et al., 2003; 2006). GST-fusion proteins
of SKAP1 failed to precipitate LFA-1 (data not shown).
Confocal real-time imaging showed that these mediators
formed dynamic clusters in response to anti-CD3 ligation.Immunity 32, 541–556, April 23, 2010 ª2010 Elsevier Inc. 551
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Figure 7. L224A Disrupts Anti-CD3-Induced ICAM-1 Binding and T cell-APC Conjugate Formation
(A) Jurkat cells transfected with vector, SKAP1, RapL, RapLDC2, or RapL-L224A were assessed for binding to ICAM-1 on micro-titer plates in response to anti-
CD3 ligation. Values expressed as a percentage of the total number of overlaid cells. Standard deviations (SDs) are based on triplicate data points per condition in
each experiment.
(B). T8.1 cells transfected with RapL-WT or RapL-L224A were cultured with L625 antigen-presenting cells in the presence or absence of tetanus toxoid (TTox)
peptide and assessed for conjugate formation. Values were expressed as a function of the T cell/APC ratio. SDs are based on triplicate data points per condition
in each experiment.
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SKAP1-RapL Mediation of TCR ‘‘Inside-Out’’ PathwayA substantial portion of these were localized in membrane vesi-
cles that further colocalized at the point of contact with anti-
CD3-ICAM1 on beads. Colocalization of RapL with SKAP1,
RapL with Rap1, and SKAP1-RapL with LFA-1 depended on
the L224A residue for SKAP1 binding, a result consistent with
the inability of anti-RapL to coprecipitate CD18 from L224A-
expressing cells, and of anti-CD18 to coprecipitate LFA-1 from
Skap1/ T cells. Although the nature of these vesicles are
unclear, they partially labeled with endosomal markers EEA1
and Rab7 and could potentially recycle and release SKAP1-
RapL-Rap1 to LFA-1. Inhibition of endosome recycling blocks
integrin-mediated adhesion of T cells (Bivona et al., 2004).
The SKAP1-RapL ‘‘inside-out’’ pathway also modulated the
motility of T cells in LNs and the dwell times with DCs. T cells
moved randomly where they were often seen to enter and reap-
pear along the nodal surface. Some 35%–40% of movement
was dependent on ICAM1 binding as observed in anti-ICAM
blocking experiments in which TCR engagement reducedmove-
ment (i.e., ‘‘stop signal’’). RapL itself slowed T cell movement in
nodes introducing the possibility it may also contribute to the
‘‘stop-signal’’ for conjugate formation (Dustin et al., 1997). It
reduced the mean average velocity and displacement (i.e.,
movement from origin) of DO11.10 T cells, a result consistent
with its ability to increase LFA-1 adhesion and T cell-APC dwell
times. It further reduced motility induced by OVA peptide and
had an antigen-independent or substitution effect in slowing
cells in the absence of peptide. The level of reduced velocity is
an underestimation given the normal limitation of transfection
(i.e., 60%–70% expression). Both slowing and increased dwell
times were SKAP1 dependent as shown by L224A reversal of
the effects. The L224A mutant resembled the GFP control in
both the absence and presence of OVA. Consistently, Skap/
T cells also show impaired slowing in LNs in response to SEA
(data not shown). Overall, our observations have identified an
‘‘inside-out’’ pathway that alters T cell behavior in lymph nodes
and contributes to the slowing of T cells for more efficient
conjugate formation and T cell responses to antigen. Chemo-
kines and coreceptors such as CTLA-4 will then add to the
mixture of signals that determine the ultimate behavior of
cells (Rudd, 2008). Motility in the LN slices showed partial sensi-
tivity to anti-CCR7 blockade (data not shown; Asperti-Boursin
et al., 2007).
In the overall scheme, the ‘‘inside-out’’ pathway would be initi-
ated by TCR-induced ADAP phosphorylation of YDDV motifs,
sites that are preferentially phosphorylated by p59fyn and that
bind the SLP-76 SH2 domain (Veale et al., 1999; Raab et al.,
1999; Geng et al., 1999) (Figure S7). ADAP is in turn closely
coupled to SKAP1 primarily via SKAP1 SH3 domain binding
to ADAP (Liu et al., 1998; Marie-Cardine et al., 1998, Kang
et al., 2000). In turn, SKAP1 regulates RapL translocation to
membranes and formation of a SKAP1-RapL-Rap1 complex.
N-SKAP1 mediates binding to C-RapL to form the SKAP1-
RapL complex, whereas anti-CD3 activates Rap1-GTP to bind(C) DO.11 T cells were transfected with RapL or RapL-L224A were labeled with CF
LN slices in the presence or absence of OVA peptide. The left panels show the mi
ence and absence of OVA peptide. The lower dot plots show displacement valu
(D) The upper panels show dot plots for contact times between transfected T cel
shows above data expressed as contact times per incidence.the RBD domain of RapL. A minimal trimeric complex would
then bind to the LFA-1 via RapL binding to K1097-K1099 resi-
dues in aL tail (Tohyama et al., 2003; Katagiri et al., 2003).
LFA-1 and SKAP1 are also recruited into lipid rafts (Krauss and
Altevogt, 1999;Wang et al., 2003). At aminimum, ADAP prevents
SKAP1 degradation to ensure sufficient levels of the effecter
protein. However, it also has a G protein and VASP binding sites
for actin remodeling and may modify adhesion events mediated
by SKAP1. Further, whereas SKAP1-RapL-Rap1 binds the
a chain of LFA-1, RIAM-talin and Kindlin 3 bind the b chain
(Moser et al., 2008; Lee et al., 2009), leading to the possible
formation of a large single complex or distinct regulatory
complexes. Rap-1 is likely to exist in distinct pools, one pool
engaged with RAPL and the second engaged with RIAM. It will
be intriguing to know whether each pool directs a different
modality of LFA-1 activation. RIAM-talin may increase affinity,
whereas the SKAP1-RAPL could direct LFA-1 vesicle fusion
and clustering. Similarly, SKAP-1 can compete for MST1 binding
leading to potential antagonism between the two proteins and
the formation of two distinct pools of RapL complexes. SKAP1
in turn intersects with RIAM via binding to its PH and RA domains
(Kliche et al., 2006; Me´nasche´ et al., 2007). Unlike in the case of
SKAP1, coexpression of RIAM did not compete for MST binding
to the SARAH domain of RapL. RIAMbinding to SKAP1 could act
to interlock a and b chains or help to terminate the response.
Subsequent ‘‘outside-in’’ signaling for altered cell shape and
motility is also dependent on SLP-76 binding to ADAP (Wang
et al., 2009).
It is also important to note that an additional unidentified signal
is needed from TCR ligation. This was shown by the fact that
anti-CD3 ligation was needed for RapL-Rap1 complex formation
even in the presence of constitutively active Rap1V12. One
attractive possibility is that phosphatidylinositol 3-kinase (PI3K)
provides this additional signal given that SKAP1 has a PH
domain that binds PI-3,4,5-P3 (PIP3) for membrane localization
(Marie-Cardine et al., 1997; Liu et al., 1998). In this model, TCR
activation of PI3K would provide the shuttle signal for SKAP1
translocation of RapL to the plasma membrane and/or proximal
vesicles. It is therefore interesting that SKAP2 dimerization via its
N-terminal domain represses the function of its adjacent PH
domain (Swanson et al., 2008). Similar residues are conserved
in SKAP1 (Liu et al., 1998). RapL could promote the opening of
the SKAP1 N-domain to allow for PH domain activation and
membrane translocation. It is also tempting to propose that the
BCR in B cells may promote the formation of an analogous
SKAP2-RapL-Rap1 complex for LFA-1 adhesion.EXPERIMENTAL PROCEDURES
Cells and Antibodies
T cells were cultured in RPMI 1640 medium with 10% (vol/vol) fetal-calf serum
and 1% (wt/vol) penicillin-streptomycin (Raab et al., 2001). Murine hybridoma
T8.1-expressing TCR specific for Ttox (830–843) and L625.7 cells were gift ofSE, whereas DCs were labeled with SNARP7. Cells were overlaid on congenic
gration of T cells (see Movie S2). The upper dot plots show velocity in the pres-
es.
ls and DCs in the presence and absence of OVA peptide. The lower histogram
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SKAP1-RapL Mediation of TCR ‘‘Inside-Out’’ PathwayO. Acuto, Oxford University. (Wang et al., 2004; Blank et al., 1993). Anti-SKAP1
(Transduction Laboratories); anti-V5 (Invitrogen); anti-myc (Upstate Biotech-
nology); anti-GFP (Santa Cruz Biotechnology); anti-human CD3 (American
Type Culture Collection); anti-mouse CD3 (2C11; hamster anti-mouse CD3)
and anti-CD18 (anti-LFA-1) (BD Biosciences); and Alexa-488 and 568-conju-
gated secondary Abs (Molecular Probes), anti-EEA1 (Abcam), anti-rab7 (Cell
Signaling), and anti-ICAM1 (R&D Systems; MN, USA) were purchased from
the manufacturers indicated. Ttox (residues 830–843) was obtained from
Research Genetics.
Generation of Plasmids and Mutagenesis
Full-length human SKAP1 cDNA were cloned into the pSRa expression vector
and in-frame with the NH2 terminus of the GFP gene (Promega). N (residues
1–104), SK (residues 209–285), SH3 (residues 285–359) and N-PH-SK (resi-
dues 1–359) domains of SKAP1 were subcloned into the pGEX-2T vector
(GE Healthcare). Human RapL was cloned into the pcDNA3.1-V5 expression
vector (Invitrogen). RapL-L224A and L253A mutants were generated by site-
direct mutagenesis (Quick Change protocol; Stratagene). Human Rap1V12
and Rap1N17 were cloned into myc-expression and pcDNA3.1-mCherry
vectors. SKAP1 and RapL were also cloned into pSR alpha HAGFP and CFP
(Stratagene). Plasmids for GST fusion proteins were transformed into the
DH5a strain of Escherichia coli and induced with isopropyl-D-thiogalactopyr-
anoside (IPTG) to produce GST fusion proteins as done previously (Kang et al.,
2000). GST, GST-full-length SKAP1, and GST-fused subdomains of SKAP1
were adsorbed to Glutathione-Sepharose 4B (GE Healthcare).
Immunoprecipitation and Blotting
Immunoprecipitation and blotting were performed as previously described
(Raab et al., 1999; 2001). For blotting, precipitates were separated by SDS-
PAGE and transferred onto nitrocellulose filters (Schleicher and Schuell).
Bound antibody was revealed with horseradish peroxidase-conjugated rabbit
anti-mouse antibody with enhanced chemiluminescence (ECL, Amersham
Biosciences). For purification of membrane fractions, Jurkat T cells were
sheared in hypotonic buffer, nuclei were removed by low-speed centrifugation
(1500 rpm, 10min), and supernatant was recentrifugated at high speed (25,000
rpm) for 1 hr. The cytosolic fraction was found in the supernatant, whereas
membranes remained in the pellet.
Confocal Microscopy
T cells were purified from Skap1+/+ and Skap1/mouse spleens as described
(Wang et al., 2007; Wang et al., 2010). Jurkat T cells were cotransfected with
expression plasmids (2–10 ug/106 cells) by microporation (Digital Bio Tech-
nology). T cells were transfected by microporation (Digital Bio Technology)
or by Nucleofector Technology from Amaxa (Lonza,Germany). For live-cell
imaging, poly-L-lysine (Sigma)-treated chambered cover slides (LabTek)
were coated with 10 mg/ml mAb OKT3 while images of the contact area
were acquired by resonance scanning confocal microscopy (TCS SP2 RS,
Leica, Heidelberg, Germany) with excitation wavelengths of 514 nm for
EYFP and 594 nm for mRFP and a 633 water-immersion objective (NA =
1.2). Images and Pearson’s correlation coefficients (PCCs) were processed
with Volocity (Improvision) and ImageJ (National Institutes of Health). T cell
conjugation assays were performed as previously described (Wang et al.,
2003, 2007). T8.1 cells were cocultured with L625.7 adhesive cells that had
been preincubated with Ttox peptide (830–943) (Blank et al., 1993). For this,
transmitted light images were acquired every 10 s during 20 min with a 403
phase objective on a Zeiss LSM510 microscope. T cell-APC interactions
were then monitored by ImageJ software.
Migration in LN Slices
Ex vivo imaging of T cells and APCs in LN slices was adapted as described
(Asperti-Boursin et al., 2007; Baje´noff,et al., 2006). In brief, inguinal mouse
LNs were embedded in low-gelling-temperature agarose (type VII-A; Sigma-
Aldrich) and sliced with a vibratome (VT 1000S; Leica). Slices were transferred
to 0.4 mm organotypic culture inserts (Millicell; Millipore). CD4+ T cells were
purified by positive selection (Dynabeadsmouse CD4 (L3T4). T cells incubated
with CFSE (Sigma, Poole, UK) and matured bone marrow-derived dendritic
cells (BMDCs) labeled with SNARF-1 (Invitrogen, Paisley, UK) were colayered
on slices. BMDCs were generated from marrow by incubation with 20 ng/ml554 Immunity 32, 541–556, April 23, 2010 ª2010 Elsevier Inc.recombinant murine GM-CSF and 1000 IU/ml IL-4. On the day 7 of culture,
BMDCs were induced to mature by addition of 1 mg/ml LPS to the cultures.
Images were acquired every 10 s during 20 min with a 203 phase objective
on a Zeiss LSM510 microscope. Cell motility was analyzed with Zeiss LSM
confocal software and Volocity software (Improvision).
Isothermal Titration Calorimetry
For ITC analysis, recombinant GST-N-SKAP1 and GST-C-RapL was bacteri-
ally expressed as described previously (Prasad et al., 1993; Raab et al.,
1995). ITC analysis was performed with the VP ITC (Microcal, Northampton,
MA, USA) (Olsson et al., 2008; Ladbury, 2004). Protein was diluted from stock
solution to the concentration required for the ITC experiment (4–10 mM) and
dialyzed against the ITC buffer 7.5 (10 mM Na-K phosphate buffer [pH 7.5]
and 150 mM NaCl). All binding data were analyzed by fitting the binding
isotherm to a simple independent binding-site model with Origin software
provided with the ITC (MicroCal).
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